glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide 1 receptor agonists:
Description
95% CI 0.74, 0.46), and cyproterone acetate/ethinyl estradiol (WMD: 0.02
These medications, which mimic hormones that regulate appetite, vary in their formulation, dosing schedules, and approved uses
But coverage changes
Fujita H, Morii T, Fujishima H, et al
Transient elastography in the diagnosis of pediatric non-alcoholic fatty liver disease and its subtypes
Antiviral agents in development for Zika virus infections
